09 May, 2024 in Investor Relations Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on May 23
25 April, 2024 in Investor Relations Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
18 April, 2024 in Investor Relations, Videos Nexalin Technology unveils positive results of clinical study for Gen-2 tACS device
09 April, 2024 in Investor Relations Nexalin Technology Accelerates Manufacturing of its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing
04 April, 2024 in Investor Relations Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device
02 April, 2024 in Investor Relations Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board
28 March, 2024 in Investor Relations Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego
14 March, 2024 in Investor Relations Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin’s Technology
13 March, 2024 in Investor Relations Nexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment”
06 March, 2024 in Investor Relations Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic Insomnia
